143 related articles for article (PubMed ID: 36825096)
1. Multiple Cranial Neuropathies Similar to Orbital Apex Syndrome Associated with Pembrolizumab: A Case Report.
Nishimura T; Sakatani T; Takeshima H; Matsuda S; Yoshizawa T; Usui K
Case Rep Oncol; 2022; 15(3):868-873. PubMed ID: 36825096
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-Induced Isolated Cranial Neuropathy: A Rare Case Report and Review of Literature.
Bruno F; Palmiero RA; Ferrero B; Franchino F; Pellerino A; Milanesi E; Soffietti R; Rudà R
Front Neurol; 2021; 12():669493. PubMed ID: 34046006
[No Abstract] [Full Text] [Related]
3. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-induced optic neuropathy - a case report.
Daetwyler E; Zippelius A; Meyer P; Läubli H
Front Immunol; 2023; 14():1171981. PubMed ID: 37228591
[TBL] [Abstract][Full Text] [Related]
5. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
Thomas S; Bae C; Joy-Ann T; Traverse W
J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
[TBL] [Abstract][Full Text] [Related]
6. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab-Induced Myasthenia Gravis and Peripheral Neuropathy: A Case Series.
McCormack SM; Hamad A
Cureus; 2023 Sep; 15(9):e44799. PubMed ID: 37809208
[TBL] [Abstract][Full Text] [Related]
8. Unexpected Adverse Events of Immune Checkpoint Inhibitors.
Shalata W; Yakobson A; Cohen AY; Goldstein I; Saleh OA; Dudnik Y; Rouvinov K
Life (Basel); 2023 Jul; 13(8):. PubMed ID: 37629514
[TBL] [Abstract][Full Text] [Related]
9. Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer.
Noguchi S; Suminaga K; Kaki T; Kawachi H; Fukao A; Terashita S; Horikawa S; Ikeue T; Sugita T
Lung Cancer (Auckl); 2020; 11():53-57. PubMed ID: 32765147
[TBL] [Abstract][Full Text] [Related]
10. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection.
Zhou C; Klionsky Y; Treasure ME; Bruno DS
Case Rep Oncol; 2019; 12(1):164-170. PubMed ID: 31043955
[TBL] [Abstract][Full Text] [Related]
13. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
[TBL] [Abstract][Full Text] [Related]
14. Orbital apex syndrome from bacterial sinusitis without orbital cellulitis.
Pfeiffer ML; Merritt HA; Bailey LA; Richani K; Phillips ME
Am J Ophthalmol Case Rep; 2018 Jun; 10():84-86. PubMed ID: 29468204
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report.
Tian CY; Ou YH; Chang SL; Lin CM
J Med Case Rep; 2021 Apr; 15(1):244. PubMed ID: 33926558
[TBL] [Abstract][Full Text] [Related]
16. Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer.
Baroz AR; Mambetsariev I; Fricke J; Pharaon R; Tan T; Kidambi T; Sandhu KS; Koczywas M; Salgia R
Cureus; 2021 Jul; 13(7):e16266. PubMed ID: 34377604
[TBL] [Abstract][Full Text] [Related]
17. Myasthenia gravis with myositis induced by pembrolizumab therapy in a patient with metastatic urothelial carcinoma.
Hayakawa N; Kikuchi E; Suzuki S; Oya M
Int Cancer Conf J; 2020 Jul; 9(3):123-126. PubMed ID: 32582515
[TBL] [Abstract][Full Text] [Related]
18. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
[TBL] [Abstract][Full Text] [Related]
19. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
[TBL] [Abstract][Full Text] [Related]
20. [Successful treatment of Guillain-Barré syndrome-like acute inflammatory demyelinating polyneuropathy caused by pembrolizumab with a combination of corticosteroid and immunoglobulins: a case report].
Hashimoto R; Ueda T; Tsuji Y; Otsuka Y; Sekiguchi K; Matsumoto R
Rinsho Shinkeigaku; 2020 Nov; 60(11):773-777. PubMed ID: 33115993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
